Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 120 Show results per page	View Search Criteria \| Help With Results


1.		Aromatase Inhibitor Clinical Trial

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Active				40 to 70				NIGMS				0412-14 UO1-GM61373-06, NCT00228956


2.		Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Active				18 to 45				Other				0501-37 NCT00352872


3.		Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				50 and over				Pharmaceutical / Industry				CFEM345DUS59 NCT00688909


4.		Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				50 and over				Other				SENORX-S07-002 NCT00699101


5.		Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 to 85				Other				20050113 NCT00243685

Last Modified: 10/9/2008 First Published: 1/1/1998


6.		Phase III Randomized Study of Letrozole Versus Placebo in Postmenopausal Women With Primary Breast Cancer Who Have Completed at Least Five Years of Adjuvant Aromatase Inhibitor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Postmenopausal				NCI, Pharmaceutical / Industry				CAN-NCIC-MA17 CALGB-49805, E-JMA17, EORTC-10983, IBCSG-BIG97-01, NCCTG-JMA17, SWOG-JMA17, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17, NCT00003140, JMA17, MA17

Last Modified: 10/9/2008 First Published: 7/1/2002


7.		Phase III Randomized Study of Two Different Schedules of Adjuvant Cyclophosphamide and Doxorubicin Versus Paclitaxel in Women With Operable Breast Cancer and 0-3 Positive Axillary Lymph Nodes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-40101 CALGB-40101, NCT00041119

Last Modified: 10/9/2008 First Published: 7/26/2003


8.		Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Premenopausal				NCI				IBCSG-2402 BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13

Last Modified: 10/5/2008 First Published: 9/24/2003


9.		Phase III Randomized Study of Four Schedules of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Patients With Node-Positive or High-Risk Node-Negative Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				SWOG-S0221 S0221, NCT00070564

Last Modified: 10/8/2008 First Published: 11/20/2003


10.		Phase III Randomized Study of Adjuvant Chemotherapy in Women With Radically Resected Loco-Regional Relapsed Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Any age				Other				IBCSG-27-02 BIG-1-02, EU-20320, NCT00074152, NSABP-B-37, EUDRACT-2005-001484-64

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute